<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE nitf SYSTEM "http://www.nitf.org/IPTC/NITF/3.3/specification/dtd/nitf-3-3.dtd">
<nitf change.date="June 10, 2005" change.time="19:30" version="-//IPTC//DTD NITF 3.3//EN">
  <head>
    <title>Corrections</title>
    <meta content="23topcorrex-2" name="slug"/>
    <meta content="23" name="publication_day_of_month"/>
    <meta content="1" name="publication_month"/>
    <meta content="2007" name="publication_year"/>
    <meta content="Tuesday" name="publication_day_of_week"/>
    <meta content="Metropolitan Desk" name="dsk"/>
    <meta content="2" name="print_page_number"/>
    <meta content="A" name="print_section"/>
    <meta content="4" name="print_column"/>
    <meta content="Technology; Corrections; New York and Region" name="online_sections"/>
    <docdata>
      <doc-id id-string="1820975"/>
      <doc.copyright holder="The New York Times" year="2007"/>
      <identified-content>
        <classifier class="indexing_service" type="descriptor">Heart</classifier>
        <classifier class="indexing_service" type="descriptor">Correction Stories</classifier>
        <classifier class="indexing_service" type="descriptor">Plavix (Drug)</classifier>
        <classifier class="indexing_service" type="descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="indexing_service" type="descriptor">Inventions and Patents</classifier>
        <classifier class="indexing_service" type="descriptor">Generic and Brand Name Products</classifier>
        <classifier class="indexing_service" type="descriptor">Suits and Litigation</classifier>
        <classifier class="indexing_service" type="descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <org class="indexing_service">Sanofi-Aventis</org>
        <org class="indexing_service">Apotex Inc</org>
        <classifier class="online_producer" type="types_of_material">Correction</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/New York and Region</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Corrections</classifier>
        <classifier class="online_producer" type="taxonomic_classifier">Top/News/Technology</classifier>
        <classifier class="online_producer" type="general_descriptor">Mergers, Acquisitions and Divestitures</classifier>
        <classifier class="online_producer" type="general_descriptor">Anatomy and Physiology</classifier>
        <classifier class="online_producer" type="general_descriptor">Generic and Brand Name Products</classifier>
        <classifier class="online_producer" type="general_descriptor">Inventions and Patents</classifier>
        <classifier class="online_producer" type="general_descriptor">Suits and Litigation</classifier>
        <classifier class="online_producer" type="general_descriptor">Drugs (Pharmaceuticals)</classifier>
        <classifier class="online_producer" type="general_descriptor">Finances</classifier>
        <classifier class="online_producer" type="general_descriptor">Medicine and Health</classifier>
      </identified-content>
    </docdata>
    <pubdata date.publication="20070123T000000" ex-ref="http://query.nytimes.com/gst/fullpage.html?res=9E05E0D71F30F930A15752C0A9619C8B63" item-length="65" name="The New York Times" unit-of-measure="word"/>
  </head>
  <body>
    <body.head>
      <hedline>
        <hl1>Corrections</hl1>
      </hedline>
      <abstract>
        <p>Correction; Jan 20 article about efforts by Bristol-Myers Squibb to recover from competitive challenge to drug Plavix misstated board's position on potential merger or takeover deals; board has not actively pursued deal</p>
      </abstract>
    </body.head>
    <body.content>
      <block class="lead_paragraph">
        <p>An article in Business Day on Saturday, about efforts by the drug maker Bristol-Myers Squibb to recover from a competitive challenge to its best-selling blood thinner, Plavix, misstated the board's position on potential merger or takeover deals involving the company. While Bristol-Myers executives have said repeatedly that they would be open to considering such deals, the board has not actively pursued a merger or sale.</p>
      </block>
      <block class="full_text">
        <p>An article in Business Day on Saturday, about efforts by the drug maker Bristol-Myers Squibb to recover from a competitive challenge to its best-selling blood thinner, Plavix, misstated the board's position on potential merger or takeover deals involving the company. While Bristol-Myers executives have said repeatedly that they would be open to considering such deals, the board has not actively pursued a merger or sale.</p>
      </block>
    </body.content>
  </body>
</nitf>
